Loading
Flow cytometry MRD counts leukaemia cells in the bone marrow one at a time by their surface proteins, down to one in ten thousand.
Eight- to ten-colour flow detects leukaemia-associated immunophenotypes or 'different-from-normal' patterns at 10^-4 sensitivity. The most widely available MRD method in AML and ALL; ELN 2021 MRD guidelines define thresholds and timepoints. Next-generation flow (EuroFlow) reaches 10^-5 in myeloma and ALL. In CLL, undetectable MRD (<10^-4) after venetoclax combinations predicts long remission and is a regulatory endpoint.
Panels of fluorescently tagged antibodies distinguish aberrant blasts from regenerating normal precursors.
Query for this technology: (TITLE:"Multiparameter flow cytometry MRD" OR ABSTRACT:"Multiparameter flow cytometry MRD") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Multiparameter flow cytometry MRD, not a curated reading list.
Shares Residual disease kinetics (BCR-ABL halving and ctDNA slopes), Immunoglobulin and T-cell receptor clonality, B-ALL risk groups (NCI criteria, ETV6::RUNX1, hyperdiploidy, hypodiploidy, iAMP21, IKZF1, CNS status), Immunoglobulin and T-cell receptor clonality testing.
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Waldenström macroglobulinaemia, Marginal zone lymphoma, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma).
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Waldenström macroglobulinaemia, Marginal zone lymphoma, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma).
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Myelodysplastic syndromes / neoplasms (MDS), Mantle cell lymphoma, Chronic lymphocytic leukaemia.
Shares Plasma cell leukaemia, Chronic lymphocytic leukaemia, first treatment, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Mantle cell lymphoma.
Shares MRD-negative complete remission, Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL), Plasma cell leukaemia, Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL).
Shares B-ALL risk groups (NCI criteria, ETV6::RUNX1, hyperdiploidy, hypodiploidy, iAMP21, IKZF1, CNS status), Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL), Standard-risk B-cell acute lymphoblastic leukaemia in children, Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL).
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia, first treatment, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.